Učitavanje...
EXTH-66. GLIOBLASTOMA CELLS FROM A PATIENT POST-TUMOR TREATING FIELDS (TTFIELDS) THERAPY ARE SENSITIVE TO TTFIELDS IN VITRO
BACKGROUND: Tumor treating fields (TTFields) are FDA-approved for treatment of newly-diagnosed and recurrent glioblastoma. TTFields have been demonstrated to extend progression-free survival and overall survival. Despite this advancement in patient outcome, many patients undergoing TTFields treatmen...
Spremljeno u:
| Izdano u: | Neuro Oncol |
|---|---|
| Glavni autori: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Oxford University Press
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5692760/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.358 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|